Print Page  |  Close Window

Investor Relations

Company Overview

Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, the Company’s gene control platform has broad potential to achieve profound and durable benefit across a range of diseases. Syros is focused on cancer and immune-mediated diseases and is advancing a growing pipeline, including its lead drug candidates SY-1425, a selective RAR? agonist for genomically defined subsets of patients identified by its platform, for a range of cancers including acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor for a range of blood cancers and solid tumors. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.

Recent Press Releases

February 27, 2017Syros Reports Discovery of Novel Genomics Based Approach to Stratifying Patients with Acute Myeloid Leukemia at Cold Spring Harbor Conference

February 21, 2017Syros’ Drug Discovery Research in Immuno-Oncology Highlighted at UCSD Moores Cancer Center Symposium

February 9, 2017Syros Announces Publication in Cell Highlighting Gene Control as Important and Rapidly Progressing Area of Research for Yielding New Medicines to Treat Cancer

February 7, 2017Syros Pharmaceuticals to Present at 2017 BIO CEO & Investor Conference

Upcoming Events

There are currently no events scheduled.

NASDAQ: SYRS0.03$11.01Volume: 17,823Today's Open: $10.71Previous Close: $10.98
Data as of 02/27/17 4:00 p.m. ETData provided by Nasdaq. Minimum 15 minutes delayed.

IR Contact

Hannah Deresiewicz
Stern Investor Relations
 hannahd@sternir.com

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever Syros Pharmaceuticals Inc posts new information to the site. Just enter your e-mail address and click Submit.